ContextVision to Unveil New Brand, AI Research, Product Updates at RSNA 2016

Image Enhancement Leader to Showcase World-Leading Product Upgrades, Investments in AI Technology

STOCKHOLM – Nov. 7, 2016 – At this year’s Annual Meeting of RSNA, ContextVision will demonstrate its wide range of leading imaging enhancement software solutions for ultrasound, X-ray based modalities and MRI.

This past year, ContextVision has made investments in artificial intelligence and deep learning. The company has been exploring the use of deep learning to optimize image quality, automatize ultrasound and organ-specific segmentation with ultrasound. VEPiO, the first AI-based prototype from ContextVision, is designed to decrease patient examination time, make ultrasound examinations more user-friendly and provide automated diagnostic confidence. This has led to the debut of the company’s new branding, which highlights their new role within artificial intelligence.

“ContextVision continues to broaden our product portfolio to give customers high quality products. We are dedicated to ensuring the best image quality for multiple modalities,” commented Anita Tollstadius, CEO, ContextVision. “We know that image quality continues to be of outmost importance for radiologists and we continuing to innovate in order to enhance the clinical value of medical imaging even further.”

In a recent machine learning competition, the Tumor Proliferation Assessment Challenge 2016, ContextVision placed second with its SLDESUTO partner (HES-SO), proving its investment in knowledge within the industry and its newest deep learning platform.

“The progression of machine learning in medical imaging is proving itself to be efficient, customizable and cost effective,” Tollstadius said. “We believe it’s important to continue to adapt to this technological shift to provide the highest quality of care to patients.”

For more information and demonstrations on these advancements in medical imaging, visit ContextVision at booth #7208 in North Building, Hall B at RSNA. To learn more about ContextVision’s collection of image enhancement software, visit

About ContextVision
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. An industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology, and is investing significantly in the field to expand the company’s product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit

Press contact
Fredrik Palm
Vice President
Phone: +46 76 870 25 43